Combining the Chemotherapeutic Effects of Epigallocatechin 3-gallate with SiRNA-mediated P53 Knock-down Results in Synergic Pro-apoptotic Effects

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2012 Dec 20

PMID 23251091

Citations 9

Authors

Ioana Berindan-Neagoe

Cornelia Braicu

Alexandru Irimie

Affiliations

Soon will be listed here.

Abstract

Plant extracts and compounds are applied to a wide variety of diseases in which traditional drugs have proven ineffective. A quickly developing trend in biomedicine is the therapeutic use of siRNA (short interfering RNA) structures. The focus of this study was on evaluating the gene expression involved in the modulation of apoptosis, in cases of combinatorial treatment (-)-epigallocatechin-3-gallate (EGCG) and/or p53siRNA. EGCG in combination with p53siRNA exerts synergic pro-apoptotic effects that are greater than those of each agent taken individually. There is a cumulative antiproliferative effect, induced by EGCG and p53siRNA treatment, and it is mediated through the activation of a large number of pro-apoptotic genes and the inhibition of anti-apoptotic protein expression levels. p53siRNA promotes the convergence of the extrinsic and intrinsic pathways in a synergic manner with EGCG. The chemotherapeutic effects of EGCG in combination with p53siRNA therapy induced a synergic pro-apoptotic effect, indicating the potential for development of promising new anticancer therapies.

Citing Articles

Apoptotic-Induced Effects of Willd. Extract in Human Colon Cancer Cells.

Chiaino E, Micucci M, Durante M, Budriesi R, Gotti R, Marzetti C Int J Mol Sci. 2020; 21(6).

PMID: 32204339 PMC: 7139529. DOI: 10.3390/ijms21062102.

Long Non-coding RNAs in Myeloid Malignancies.

Zimta A, Tomuleasa C, Sahnoune I, Calin G, Berindan-Neagoe I Front Oncol. 2019; 9:1048.

PMID: 31681586 PMC: 6813191. DOI: 10.3389/fonc.2019.01048.

-saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells.

Obasi T, Braicu C, Iacob B, Bodoki E, Jurj A, Raduly L Cancer Manag Res. 2018; 10:5709-5724.

PMID: 30532593 PMC: 6245348. DOI: 10.2147/CMAR.S163328.

The Unforeseen Non-Coding RNAs in Head and Neck Cancer.

Irimie A, Zimta A, Ciocan C, Mehterov N, Dudea D, Braicu C Genes (Basel). 2018; 9(3).

PMID: 29494516 PMC: 5867855. DOI: 10.3390/genes9030134.

Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate.

Min K, Kwon T Integr Med Res. 2017; 3(1):16-24.

PMID: 28664074 PMC: 5481703. DOI: 10.1016/j.imr.2013.12.001.

References

Storvold G, Andersen T, Perou C, Frengen E . siRNA: a potential tool for future breast cancer therapy?. Crit Rev Oncog. 2006; 12(1-2):127-50. DOI: 10.1615/critrevoncog.v12.i1-2.70. View

Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A . TRAIL receptor signalling and modulation: Are we on the right TRAIL?. Cancer Treat Rev. 2009; 35(3):280-8. DOI: 10.1016/j.ctrv.2008.11.006. View

Wang M, Windgassen D, Papoutsakis E . A global transcriptional view of apoptosis in human T-cell activation. BMC Med Genomics. 2008; 1:53. PMC: 2600644. DOI: 10.1186/1755-8794-1-53. View

Tudoran O, Soritau O, Balacescu O, Balacescu L, Braicu C, Rus M . Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells. J Cell Mol Med. 2011; 16(3):520-30. PMC: 3822928. DOI: 10.1111/j.1582-4934.2011.01346.x. View

Nakazato T, Ito K, Ikeda Y, Kizaki M . Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res. 2005; 11(16):6040-9. DOI: 10.1158/1078-0432.CCR-04-2273. View

Dyer M, MacFarlane M, Cohen G . Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol. 2007; 25(28):4505-6. DOI: 10.1200/JCO.2007.13.1011. View

Tachibana H . Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr. 2009; 61:156-169. DOI: 10.1159/000212748. View

Peperzak V, Veraar E, Keller A, Xiao Y, Borst J . The Pim kinase pathway contributes to survival signaling in primed CD8+ T cells upon CD27 costimulation. J Immunol. 2010; 185(11):6670-8. DOI: 10.4049/jimmunol.1000159. View

Ashkenazi A . Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6):420-30. DOI: 10.1038/nrc821. View

10.

Qin J, Xie L, Zheng X, Wang Y, Bai Y, Shen H . A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun. 2007; 354(4):852-7. DOI: 10.1016/j.bbrc.2007.01.003. View

11.

Castanotto D, Rossi J . The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009; 457(7228):426-33. PMC: 2702667. DOI: 10.1038/nature07758. View

12.

Kanadzu M, Lu Y, Morimoto K . Dual function of (--)-epigallocatechin gallate (EGCG) in healthy human lymphocytes. Cancer Lett. 2005; 241(2):250-5. DOI: 10.1016/j.canlet.2005.10.021. View

13.

Golden E, Lam P, Kardosh A, Gaffney K, Cadenas E, Louie S . Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009; 113(23):5927-37. DOI: 10.1182/blood-2008-07-171389. View

14.

Denoeud J, Moser M . Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol. 2010; 89(2):195-203. DOI: 10.1189/jlb.0610351. View

15.

Fridman J, Lowe S . Control of apoptosis by p53. Oncogene. 2003; 22(56):9030-40. DOI: 10.1038/sj.onc.1207116. View

16.

Nandakumar V, Singh T, Katiyar S . Multi-targeted prevention and therapy of cancer by proanthocyanidins. Cancer Lett. 2008; 269(2):378-87. PMC: 2562893. DOI: 10.1016/j.canlet.2008.03.049. View

17.

Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H . Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006; 66(5):2500-5. DOI: 10.1158/0008-5472.CAN-05-3636. View

18.

Aggarwal B . Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003; 3(9):745-56. DOI: 10.1038/nri1184. View

19.

Sigal A, Rotter V . Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2001; 60(24):6788-93. View

20.

Ashkenazi A, Dixit V . Death receptors: signaling and modulation. Science. 1998; 281(5381):1305-8. DOI: 10.1126/science.281.5381.1305. View